Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VBIR-2 (PF-06936308) in Advanced NSCLC and TNBC
NCT03674827Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Adenoviral Vectors, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of PF-06936308 in non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), Number of Participants With AEs as Graded by NCI CTCAE v5.0 (Grade >=3) and 6 more. Started Nov 2018; status: terminated.
02
Drugs
PF-06936308
03
Conditions
non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03674827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03674827.